Biovica International - Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress |
| April 17, 2018 | April 2018 Bond Updates |
|
UPPSALA, Sweden, April 17, 2018 /PRNewswire/ --
New results from a Pfizer study on Ibrance® (palbociclib, Pfizer) of women with metastatic breast cancer demonstrate that DiviTum can provide fast evaluation of biologic effect demonstrating CDK 4/6 inhibition.
The study, presented... |
| View more at: https://www.prnewswire.com/news-releases/biovica-international---positive-results-with-divitum-from-new-pfizer-study-presented-at-the-aacr-congress-300631000.html |
| Related News |
|